Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00831441 · ClinicalTrials.gov registry record · Phase 3
Phase III Acute Coronary Syndrome
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 3
- Development phase
- 7,484
- Enrollment target
NCT00831441 is a Phase 3 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 7,484 participants.
The verdict
NCT00831441, a Phase 3 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 7,484 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if apixaban is superior to placebo for preventing cardiovascular death, non-fatal myocardial infarction, or ischemic stroke in subjects with a recent acute coronary syndrome
Interventions
- DRUG Placebo
- DRUG Apixaban
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7,484 participants |
| Start Date | 2009-03 |
| Est. Completion | 2011-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00831441
The ClinicalTrials.gov registry entry for NCT00831441 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 7,484 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00831441 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00831441 about?
NCT00831441 is a clinical study titled "Phase III Acute Coronary Syndrome". The purpose of this study is to determine if apixaban is superior to placebo for preventing cardiovascular death, non-fatal myocardial infarction, or ischemic stroke in subjects with a recent acute coronary syndrome
What is the current status of trial NCT00831441?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 7,484 participants. The study started on 2009-03. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00831441?
The interventions under investigation include: Placebo (DRUG), Apixaban (DRUG).
Who is sponsoring clinical trial NCT00831441?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.